Another 346 kinds of drugs have been removed from medical insurance. What should pharmaceutical companies do in the future

[industry trends of pharmaceutical network] recently, Sichuan Medical Security Bureau issued a document Since January 1, 2020, the basic medical insurance, work-related injury insurance and maternity insurance of Sichuan Province have fully implemented the national drug catalog, and the generic name, drug classification, dosage form and limited payment scope of drugs have been implemented in accordance with the national regulations According to the national drug catalog, 275 Western medicines and 71 Chinese patent medicines will be completely removed from the medical insurance catalog of Sichuan Province Photo source: provinces and cities have adjusted the medical insurance catalog In fact, Sichuan Province is not the first one At present, many provinces and cities have begun to adjust the medical insurance catalog For example, Tianjin Medical Insurance Bureau recently issued the notice of municipal human resources and Social Security Bureau of Tianjin Medical Insurance Bureau on docking the work of national drug catalog in 2019 It can be found that at present, Tianjin has eliminated the national key monitoring drugs and the varieties out of the national health insurance catalog in the current round of national health insurance catalog adjustment Although there is no mention of clearing up the original local supplementary varieties of medical insurance, I believe it will be sooner or later under the requirements of national policies On December 13, Hunan Province issued a document, which made it clear that it would strictly implement the newly issued catalogue of Medicare drugs and the unified national payment standard for drugs negotiated by the state Among them, after the first batch of national key monitoring catalog varieties are removed preferentially and the original catalog varieties of the province that have entered the national drug catalog are transferred out, they are classified as "drugs within the digestion period" These varieties will be digested year by year within three years according to the national regulations, and a total of 404 drugs are within the transfer out range, including 212 western drugs and 192 Chinese patent drugs In addition, nine departments, including Jiangsu medical insurance bureau, recently jointly issued the implementation plan of Jiangsu Province to promote the implementation of the pilot drug centralized procurement and use pilot project and expand the regional scope, clarifying the implementation of the national pilot expansion results and supporting policies by December 31 of this year It is estimated that the average price of 25 drugs selected in this round of procurement will be reduced by 59% after landing in Jiangsu, saving 2.6 billion yuan annually From the current situation, with the new version of the medical insurance catalog about to be officially implemented, many provinces and regions have issued a notice on the local adjustment of the medical insurance catalog Some insiders said that in combination with the continuous promotion of consistency evaluation, focusing on the monitoring catalog, dynamic adjustment of medical insurance catalog and other policies, China's clinical drug market may see a large-scale reshuffle in the next three years For pharmaceutical companies, the impact of these policies is also huge Due to the unified national standards, the power of local supplement has been basically cancelled, which will have a great impact on the varieties and enterprises that only rely on entering the local supplement catalogue to support sales In order to reduce the impact of being "kicked out" of the directory as much as possible, more and more voices in the industry say that pharmaceutical companies need to seek other markets, and the key words mentioned are grassroots, out of hospital and Internet At present, multinational pharmaceutical companies are constantly increasing their efforts to sink the grassroots For example, according to a group of data previously released by iqvia, the growth rate of multinational pharmaceutical companies in second tier and third tier cities is 10.9% and 11.9% respectively In addition to the primary and out of hospital markets, the chronic disease market also has great development potential According to statistics, there are nearly 300 million chronic disease patients in China, which is a very large chronic disease group in the world The prevention and control of chronic diseases are also mentioned in many national policies For example, in the opinions of the relevant departments on the implementation of the healthy China action, they directly name chronic diseases such as cardiovascular and cerebrovascular diseases, chronic respiratory diseases, diabetes, cancer and so on, which require strengthening prevention and control actions In addition, with the explosive growth of the network, the concept of "Internet +" has been continuously upgraded and has penetrated into all walks of life, from the renewal and iteration of concepts to the rapid reshuffle of the industry pattern More and more traditional industries began to actively increase their own interests with the help of Internet platforms, including the pharmaceutical industry On November 19, 111 group, China's leading Internet medicine and health enterprise, reached strategic cooperation with Tianjin Tongrentang Both sides announced that they would realize resource sharing and complementary advantages in terms of online online and offline channel penetration, product promotion, big data, brand awareness and patient education.